Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly is experiencing explosive growth thanks ... According to data compiled by Coherent Market Insights, the global oncology drug market is expected to be worth $533 billion by 2031 ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

In a phase 2 study, treatment with the oral GLP-1 drug reduced patients' weight by 14.7% after just 36 weeks. In addition to diabetes and weight loss treatments, Eli Lilly is a big player in the ...

However, Eli Lilly recently surprised investors ... as it has several new drugs to treat conditions like cancer, ulcerative colitis, and Alzheimer's disease. If Lilly is correct in its assessment ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion ... The new deal centers on a Scorpion drug called STX-478, which is designed to inhibit mutations ...